Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1792044 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $17.76Day −0.34%Mkt cap $20.8B1Y +105.1%Off 52W high −1.7%Vol (1Y) 32.5%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,361 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest4.1% of sh out |
| Days to cover5.2d |
| 13F net flow (QoQ)+1.41% |
| Top-10 13F concentration54.0% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$14.56B |
| Earnings (TTM)-$3.51B |
| Net margin−24.6% |
| ROIC−7.0% |
| Total debt / EBITDA106.59× |
| Sales growth 3Y−4.2% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+44.9% |
| 1Y+105.1% |
| 3Y+92.0% |
| 5Y+55.8% |
| Since incept. (ann.)+6.7% |
Total return through 2026-07-30 · series begins 2021-02-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)32.5% |
| Ann. volatility (3Y)32.1% |
| Sharpe (1Y)2.35 |
| Sharpe (3Y)0.85 |
| Max drawdown (1Y)−19.0% |
| Max drawdown (3Y)−45.0% |
| Beta (3Y vs SPY)0.93 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 84.4M | $1.1B | 7.33% | −2.8% |
| Davis Selected Advisers | 78.2M | $1.1B | 6.79% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 74.7M | $1.0B | 6.49% | new |
| PRICE T ROWE ASSOCIATES INC /MD/ | 65.9M | $890M | 5.72% | −16.7% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 53.9M | $728M | 4.68% | new |
| STATE STREET CORP | 52.2M | $706M | 4.54% | −5.6% |
| DIMENSIONAL FUND ADVISORS LP | 38.3M | $518M | 3.33% | −4.3% |
| Rubric Capital Management LP | 33.5M | $453M | 2.91% | +31.4% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | $0.15 | — | $3.52B | +8.1% |
| 2025-12-31 | 2026-02-26 | — | — | $3.70B | +5.0% |
| 2025-09-30 | 2025-11-06 | −$0.11 | −237.5% | $3.76B | +0.2% |
| 2025-06-30 | 2025-08-07 | $0.00 | — | $3.58B | −5.6% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
US 59% · CN 41%
geographic · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
